tiprankstipranks
Trending News
More News >
Sutro Biopharma Inc (STRO)
NASDAQ:STRO
US Market
Advertisement

Sutro Biopharma (STRO) Stock Forecast & Price Target

Compare
686 Followers
See the Price Targets and Ratings of:

STRO Analyst Ratings

Hold
5Ratings
Hold
2 Buy
2 Hold
1 Sell
Based on 5 analysts giving stock ratings to
Sutro
Biopharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

STRO Stock 12 Month Forecast

Average Price Target

$1.70
▲(84.78%Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Sutro Biopharma in the last 3 months. The average price target is $1.70 with a high forecast of $2.00 and a low forecast of $0.80. The average price target represents a 84.78% change from the last price of $0.92.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","-1":"-$1","0.75":"$0.75","2.5":"$2.5","4.25":"$4.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.80</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.75,2.5,4.25,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.68,0.7815384615384615,0.8830769230769231,0.9846153846153847,1.086153846153846,1.1876923076923078,1.2892307692307692,1.3907692307692305,1.4923076923076923,1.5938461538461537,1.6953846153846155,1.7969230769230768,1.8984615384615382,{"y":2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.68,0.7584615384615385,0.836923076923077,0.9153846153846155,0.9938461538461538,1.0723076923076924,1.1507692307692308,1.2292307692307691,1.3076923076923077,1.3861538461538463,1.4646153846153847,1.543076923076923,1.6215384615384614,{"y":1.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.68,0.6892307692307693,0.6984615384615385,0.7076923076923077,0.716923076923077,0.7261538461538461,0.7353846153846154,0.7446153846153847,0.7538461538461538,0.7630769230769231,0.7723076923076924,0.7815384615384615,0.7907692307692308,{"y":0.8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.32,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.74,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.77,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.57,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.55,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.75,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.59,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.9,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.68,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$2.00Average Price Target$1.70Lowest Price Target$0.80
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on STRO
TipRanks AITipRanks
Not Ranked
TipRanks
$0.5
Sell
-45.65%
Downside
Reiterated
07/23/25
Sutro Biopharma's overall score is heavily impacted by its poor financial performance, with persistent losses and negative cash flows being significant concerns. The technical and valuation metrics further underscore the company's current weak position in the market. Corporate events, such as the NASDAQ non-compliance notice, add additional risk factors.
Piper Sandler Analyst forecast on STRO
Edward TenthoffPiper Sandler
Piper Sandler
$2
Buy
117.39%
Upside
Upgraded
06/16/25
Sutro Biopharma upgraded to Overweight from Neutral at Piper SandlerSutro Biopharma upgraded to Overweight from Neutral at Piper Sandler
Bank of America Securities Analyst forecast on STRO
Tazeen AhmadBank of America Securities
Bank of America Securities
$1$0.8
Sell
-13.04%
Downside
Reiterated
05/19/25
Bank of America Securities Remains a Sell on Sutro Biopharma (STRO)
Wedbush
$2
Hold
117.39%
Upside
Reiterated
05/09/25
Sutro Biopharma (STRO) Receives a Hold from Wedbush
H.C. Wainwright Analyst forecast on STRO
Andres Y. MaldonadoH.C. Wainwright
H.C. Wainwright
$2
Hold
117.39%
Upside
Reiterated
05/09/25
Sutro Biopharma: Hold Rating Amid Strategic Transition and Preclinical Focus
TD Cowen
Buy
Reiterated
05/09/25
TD Cowen Remains a Buy on Sutro Biopharma (STRO)
Oppenheimer Analyst forecast on STRO
Jay OlsonOppenheimer
Oppenheimer
Hold
Downgraded
03/14/25
Sutro Biopharma downgraded to Perform from Outperform at OppenheimerSutro Biopharma downgraded to Perform from Outperform at Oppenheimer
Truist Financial Analyst forecast on STRO
Asthika GoonewardeneTruist Financial
Truist Financial
Buy
Reiterated
03/14/25
Truist Financial Reaffirms Their Buy Rating on Sutro Biopharma (STRO)
Jefferies Analyst forecast on STRO
Roger SongJefferies
Jefferies
$20$8
Buy
769.57%
Upside
Reiterated
03/14/25
Sutro Biopharma (STRO) PT Lowered to $8 at JefferiesJefferies analyst Roger Song lowered the price target on Sutro Biopharma (NASDAQ: STRO) to $8.00 (from $20.00) while maintaining a Buy rating.
Citizens JMP Analyst forecast on STRO
Reni BenjaminCitizens JMP
Citizens JMP
Hold
Downgraded
03/14/25
Sutro Biopharma (STRO) was downgraded to a Hold Rating at JMP Securities
Wells Fargo Analyst forecast on STRO
Derek ArchilaWells Fargo
Wells Fargo
$4
Hold
334.78%
Upside
Reiterated
03/13/25
Cautious Hold Rating on Sutro Biopharma Amid Strategic Shift and Restructuring
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on STRO
TipRanks AITipRanks
Not Ranked
TipRanks
$0.5
Sell
-45.65%
Downside
Reiterated
07/23/25
Sutro Biopharma's overall score is heavily impacted by its poor financial performance, with persistent losses and negative cash flows being significant concerns. The technical and valuation metrics further underscore the company's current weak position in the market. Corporate events, such as the NASDAQ non-compliance notice, add additional risk factors.
Piper Sandler Analyst forecast on STRO
Edward TenthoffPiper Sandler
Piper Sandler
$2
Buy
117.39%
Upside
Upgraded
06/16/25
Sutro Biopharma upgraded to Overweight from Neutral at Piper SandlerSutro Biopharma upgraded to Overweight from Neutral at Piper Sandler
Bank of America Securities Analyst forecast on STRO
Tazeen AhmadBank of America Securities
Bank of America Securities
$1$0.8
Sell
-13.04%
Downside
Reiterated
05/19/25
Bank of America Securities Remains a Sell on Sutro Biopharma (STRO)
Wedbush
$2
Hold
117.39%
Upside
Reiterated
05/09/25
Sutro Biopharma (STRO) Receives a Hold from Wedbush
H.C. Wainwright Analyst forecast on STRO
Andres Y. MaldonadoH.C. Wainwright
H.C. Wainwright
$2
Hold
117.39%
Upside
Reiterated
05/09/25
Sutro Biopharma: Hold Rating Amid Strategic Transition and Preclinical Focus
TD Cowen
Buy
Reiterated
05/09/25
TD Cowen Remains a Buy on Sutro Biopharma (STRO)
Oppenheimer Analyst forecast on STRO
Jay OlsonOppenheimer
Oppenheimer
Hold
Downgraded
03/14/25
Sutro Biopharma downgraded to Perform from Outperform at OppenheimerSutro Biopharma downgraded to Perform from Outperform at Oppenheimer
Truist Financial Analyst forecast on STRO
Asthika GoonewardeneTruist Financial
Truist Financial
Buy
Reiterated
03/14/25
Truist Financial Reaffirms Their Buy Rating on Sutro Biopharma (STRO)
Jefferies Analyst forecast on STRO
Roger SongJefferies
Jefferies
$20$8
Buy
769.57%
Upside
Reiterated
03/14/25
Sutro Biopharma (STRO) PT Lowered to $8 at JefferiesJefferies analyst Roger Song lowered the price target on Sutro Biopharma (NASDAQ: STRO) to $8.00 (from $20.00) while maintaining a Buy rating.
Citizens JMP Analyst forecast on STRO
Reni BenjaminCitizens JMP
Citizens JMP
Hold
Downgraded
03/14/25
Sutro Biopharma (STRO) was downgraded to a Hold Rating at JMP Securities
Wells Fargo Analyst forecast on STRO
Derek ArchilaWells Fargo
Wells Fargo
$4
Hold
334.78%
Upside
Reiterated
03/13/25
Cautious Hold Rating on Sutro Biopharma Amid Strategic Shift and Restructuring
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sutro Biopharma

1 Month
xxx
Success Rate
6/16 ratings generated profit
38%
Average Return
-2.93%
upgraded a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 37.50% of your transactions generating a profit, with an average return of -2.93% per trade.
3 Months
xxx
Success Rate
5/16 ratings generated profit
31%
Average Return
-15.66%
upgraded a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 31.25% of your transactions generating a profit, with an average return of -15.66% per trade.
1 Year
Edward TenthoffPiper Sandler
Success Rate
4/16 ratings generated profit
25%
Average Return
-40.29%
upgraded a buy rating last month
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -40.29% per trade.
2 Years
xxx
Success Rate
1/14 ratings generated profit
7%
Average Return
-64.71%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 7.14% of your transactions generating a profit, with an average return of -64.71% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

STRO Analyst Recommendation Trends

Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
7
3
1
1
1
Buy
4
2
3
1
1
Hold
7
7
11
7
7
Sell
1
1
3
5
6
Strong Sell
0
0
0
0
0
total
19
13
18
14
15
In the current month, STRO has received 2 Buy Ratings, 7 Hold Ratings, and 6 Sell Ratings. STRO average Analyst price target in the past 3 months is 1.70.
Each month's total comprises the sum of three months' worth of ratings.

STRO Financial Forecast

STRO Earnings Forecast

Next quarter’s earnings estimate for STRO is -$0.38 with a range of -$0.64 to -$0.04. The previous quarter’s EPS was -$0.91. STRO beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 48.74% of the time in the same period. In the last calendar year STRO has Outperformed its overall industry.
Next quarter’s earnings estimate for STRO is -$0.38 with a range of -$0.64 to -$0.04. The previous quarter’s EPS was -$0.91. STRO beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 48.74% of the time in the same period. In the last calendar year STRO has Outperformed its overall industry.

STRO Sales Forecast

Next quarter’s sales forecast for STRO is $15.84M with a range of $8.51M to $24.50M. The previous quarter’s sales results were $17.40M. STRO beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 50.42% of the time in the same period. In the last calendar year STRO has Outperformed its overall industry.
Next quarter’s sales forecast for STRO is $15.84M with a range of $8.51M to $24.50M. The previous quarter’s sales results were $17.40M. STRO beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 50.42% of the time in the same period. In the last calendar year STRO has Outperformed its overall industry.

STRO Stock Forecast FAQ

What is STRO’s average 12-month price target, according to analysts?
Based on analyst ratings, Sutro Biopharma Inc’s 12-month average price target is 1.70.
    What is STRO’s upside potential, based on the analysts’ average price target?
    Sutro Biopharma Inc has 84.78% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is STRO a Buy, Sell or Hold?
          Sutro Biopharma Inc has a consensus rating of Hold which is based on 2 buy ratings, 2 hold ratings and 1 sell ratings.
            What is Sutro Biopharma Inc’s price target?
            The average price target for Sutro Biopharma Inc is 1.70. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $2.00 ,the lowest forecast is $0.80. The average price target represents 84.78% Increase from the current price of $0.92.
              What do analysts say about Sutro Biopharma Inc?
              Sutro Biopharma Inc’s analyst rating consensus is a Hold. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of STRO?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis